title: Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.
abstract: Augmentation of the peak bone mass (PBM) may be one of the most effective interventions to reduce the risk of developing osteoporosis later in life; however treatments to augment PBM are currently limited. Our study evaluated whether a greater PBM could be achieved either in the progesterone nuclear receptor knockout mice (PRKO) or by using a nuclear progesterone receptor (nPR) antagonist, RU486 in mice. Compared to their wild type (WT) littermates the female PRKO mice developed significantly higher cancellous and cortical mass in the distal femurs, and this was associated with increased bone formation. The high bone mass phenotype was partially reproduced by administering RU486 in female WT mice from 1-3 months of age. Our results suggest that the inhibition of the nPR during the rapid bone growth period (1-3 months) increases osteogenesis, which results in acquisition of higher bone mass. Our findings suggest a crucial role for progesterone signaling in bone acquisition and inhibition of the nPR as a novel approach to augment bone mass, which may have the potential to reduce the burden of osteoporosis.
authors.affiliation: Department of Internal Medicine, Center for Healthy Aging, University of California Davis Medical Center, Sacramento, California, United States of America. wei.yao@ucdmc.ucdavis.edu
authors.forename: Wei
authors.initials: W
authors.lastname: Yao
authors.forename: Weiwei
authors.initials: W
authors.lastname: Dai
authors.forename: Mohammad
authors.initials: M
authors.lastname: Shahnazari
authors.forename: Aaron
authors.initials: A
authors.lastname: Pham
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Chen
authors.forename: Haiyan
authors.initials: H
authors.lastname: Chen
authors.forename: Min
authors.initials: M
authors.lastname: Guan
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Lane
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D001835:Body Weight / Q000187:drug effects / Q000235:genetics; D015519:Bone Density / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D001846:Bone Development / Q000187:drug effects* / Q000235:genetics; D001862:Bone Resorption / Q000235:genetics; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D015735:Mifepristone / Q000494:pharmacology; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D012737:Sex Factors
chemical_list: D006727:Hormone Antagonists; D011980:Receptors, Progesterone; D015735:Mifepristone